1-((2R,3R,4S,5S)-5-((S)-((2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yloxy)(1-(3-(4-benzoylphenoxy)propyl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione

ID: ALA4555693

Chembl Id: CHEMBL4555693

PubChem CID: 72701427

Max Phase: Preclinical

Molecular Formula: C32H36N6O11

Molecular Weight: 680.67

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  NC[C@H]1O[C@@H](O[C@@H](c2cn(CCCOc3ccc(C(=O)c4ccccc4)cc3)nn2)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C32H36N6O11/c33-15-21-24(41)27(44)31(47-21)49-28(29-25(42)26(43)30(48-29)38-13-11-22(39)34-32(38)45)20-16-37(36-35-20)12-4-14-46-19-9-7-18(8-10-19)23(40)17-5-2-1-3-6-17/h1-3,5-11,13,16,21,24-31,41-44H,4,12,14-15,33H2,(H,34,39,45)/t21-,24-,25+,26-,27-,28+,29+,30-,31+/m1/s1

Standard InChI Key:  BBETYYOPWHBNMD-WRMCITQMSA-N

Alternative Forms

1. Alternative Forms:

   

   ALA4555693

   1-[(2R,3R,4S,5S)-5-[(S)-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-[1-[3-(4-benzoylphenoxy)propyl]triazol-4-yl]methyl]-3,4-dihydroxyoxolan-2-yl]pyrimidine-2,4-dione;2,2,2-trifluoroacetic acid

2. Parent:

   

   ALA4555693

   1-[(2R,3R,4S,5S)-5-[(S)-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-[1-[3-(4-benzoylphenoxy)propyl]triazol-4-yl]methyl]-3,4-dihydroxyoxolan-2-yl]pyrimidine-2,4-dione

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 680.67

Molecular Weight (Monoisotopic): 680.2442

AlogP: -1.39

#Rotatable Bonds: 13

Polar Surface Area: 246.50

Molecular Species: BASE

HBA: 16

HBD: 6

#RO5 Violations: 3

HBA (Lipinski): 17

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 9.70

CX Basic pKa: 8.75

CX LogP: -0.72

CX LogD: -1.84

Aromatic Rings: 4

Heavy Atoms: 49

QED Weighted: 0.07

Np Likeness Score: 0.23

References

1. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

Source

Source(1):

• Scientific Literature